Business Trends– category –
-
FDA Lifts Clinical Hold on Intellia Therapeutics’ Phase 3 Trial for nex-z in Transthyretin Amyloidosis
Intellia Therapeutics (via LinkedIn) USA Overview Intellia Therapeutics announced the FDA has lifted the clinical hold on its Phase 3 MAGNITUDE-2 clinical trial for nexiguran ziclumeran (nex-z), a therapeutic candidate for transthyretin ... -
Intellia Therapeutics’ Gene-Editing Therapy lonvo-z Achieves 87% Reduction in HAE Attacks and 62% Attack-Free Rate in Phase 3 Trial
The Motley Fool USA Overview Intellia Therapeutics announced its in vivo gene-editing therapy, lonvoguran ziclumeran (lonvo-z), successfully met all primary and secondary endpoints in the Phase 3 HAELO trial for hereditary angioedema (HA... -
Regenerative and Gene Therapies for Rare Diseases Achieve Key Clinical Milestones, Including iPSC for Retinitis Pigmentosa and Gene Therapy for Pediatric Hearing Loss
RegMedNet UK Overview Significant clinical milestones have been reached in regenerative and gene therapies for rare diseases. Sumitomo Pharma America has dosed the first patient in a Phase I/IIa trial of its iPSC-derived cell therapy for... -
Extracellular Vesicles Emerge as Promising Biomarkers and Therapeutics for Cardiovascular Disease
Exosome-RNA.com USA Overview Researchers at Massachusetts General Hospital have highlighted the significant potential of extracellular vesicles (EVs) as both diagnostic biomarkers and therapeutic agents for cardiovascular diseases (CVD).... -
NVIDIA Leads $500 Billion Private Equity Investment to Accelerate Global AI Infrastructure and Power Solutions
Microgrid Knowledge USA Overview NVIDIA has announced its leadership in a colossal $500 billion private equity investment, in partnership with Blackstone, BlackRock, and Apollo, aimed at AI infrastructure and power solutions. This landma... -
Amgen Terminates $500M+ Collaboration with TScan, TScan CEO Affirms No Impact on Core Strategy
Fierce Biotech USA Overview Amgen has scrapped its over $500 million collaboration with TScan Therapeutics focused on immune cell therapy development. Despite this, TScan's CEO asserted that the termination would not affect the company's... -
Eli Lilly Forges Partnership with Gateway Labs Alumnus to Develop Trans-Amplifying RNA Vaccine Platform for Infectious Diseases
Fierce Biotech USA Overview Eli Lilly has announced a strategic partnership with a Gateway Labs alumnus company to advance a trans-amplifying RNA (taRNA) vaccine platform for infectious diseases. This collaboration aims to bolster Lilly'... -
NYC Bar Association Issues Formal Opinion on Ethical Use of AI for Non-Client Conversation Recording and Summarization
New York City Bar Association USA Overview The New York City Bar Association released Formal Opinion 2026-2, addressing the ethical implications of using AI tools to record, transcribe, and summarize non-client conversations. The opinion... -
Major AI Acquisitions: Stripe Buys OpenRouter for $7B+, SpaceX Acquires Cursor for $60B
Superpower Daily USA Overview Several significant M&A activities have been reported in the AI sector. Stripe completed its acquisition of OpenRouter, an AI model gateway serving 8 million developers, for over $7 billion. Separately, ... -
Nuvvon Secures $5.3M Seed Funding for Safe, Room-Temperature Solid Polymer Electrolyte Solid-State Batteries, Free of Sulfides and Oxides
Shanghai Metals Market (SMM) USA Overview U.S. solid-state battery startup Nuvvon has raised $5.3 million in seed funding to commercialize its pure solid polymer electrolyte (SPE) technology, enabling high-safety, high-energy-density, an...
